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background:  A consensus on what constitutes a clinically meaningful periprocedural myocardial infarction (PMI) remains debated. We evaluated 
the accuracy of two PMI definitions currently implemented for quality outcome assessment and clinical trial end points.
methods: Patients undergoing elective PCI with normal baseline troponin-I and CK-MB were included. PMI was defined according to either the 
2007 Task Force (NCDR® CathPCI Registry®) definition or the updated 2012 Task Force definition. Multivariate analysis was performed for the end 
point of 1-year all-cause death or MI.
results: Of 7,333 patients included, 31.9% and 2.1% were identified as having a PMI by NCDR or 2012 definition, respectively. Mean age 66 ± 11 
years; 66.8% males, 1.4 ± 0.9 stents implanted per patient, 84.5% bivalirudin use, and 29.7 type C lesions. Death or MI occurred in 5.6% of NCDR 
and 6.6% of 2012 defined patients. Neither biomarker was independently associated with death or MI for either definition (NCDR OR 1.1; 95% CI 
0.9-1.5, p=0.34; 2012 Task Force OR 1.4; 95% CI 0.7-3.0, p=0.38). Only a modest correlation exists for either definition to predict death or MI, 
(Figure 1) which did not improve for the 2012 definition.
Conclusions: PMI definitions currently used for catheterization lab quality metrics and those used for clinical trial end points have poor 
discrimination for adverse events. While the 2012 definition drastically reduced the number of PMIs defined, it did not improve the predictive 
accuracy over the NCDR definition.
 
